InVivoMAb Anti-SARS-CoV-2 RBD (JN.1) Neutralizing Antibody (Iv0221)
Produktgrößen
100 ug
£384,00
VVV00311-100UG
1 mg
£988,00
VVV00311-1MG
5 mg
£2913,00
VVV00311-5MG
Über dieses Produkt
- SKU:
- VVV00311
- Zusätzliche Namen:
- Spike glycoprotein, S glycoprotein, Spike protein S1, Receptor-Binding Domain, RBD, JN.1, SARS-CoV-2 (2019-nCoV)
- Anwendung:
- Block/Inhibit/Neutralise, ELISA
- Buffer:
- 0.01M PBS, pH 7.4.
- translate.label.attr.clone:
- Iv0221
- Klonalität:
- Monoclonal, Recombinant Monoclonal
- Konzentration:
- 1.8 mg/ml
- Host:
- Human
- Immunogen:
- Spike glycoprotein, S glycoprotein, Spike protein S1, Receptor-Binding Domain, RBD, JN.1, SARS-CoV-2 (2019-nCoV)
- Isotyp:
- IgG1, kappa
- Physischer Zustand:
- Liquid
- Reinheit:
- >95%
- Aufreinigung:
- Protein A/G purified from cell culture supernatant.
- Reaktivitäten:
- Virus
- Versandbedingungen:
- Blue Ice
- Lagerbedingungen:
- -20[o]C Avoid freeze/thaw cycles., 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Hersteller:
- AntibodySystem
- Typ:
- Antibody: Recombinant Antibodies
- Datenblatt des Herstellers:20928.html